Biotech IV Monitor

ORKA — Oruka Therapeutics Inc.

$5.6B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Oruka Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is October 2027.

Next readoutOctober 2027in ~11 months
Upcoming readouts4none in Phase 3
Market cap$5.6B
Cash & investments$1.21B~24 quarters at last loss rate
Recent 8-K filings1latest 2026-10-26

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2 ORKA-001
Plaque Psoriasis · NCT07290569
October 2026
Primary data collected

Upcoming readouts

Phase 2 ORKA-002
Plaque Psoriasis · NCT07474792
October 2027
Ongoing
Phase 2 ORKA-002
Hidradenitis Suppurativa (HS) · NCT07783542
October 2028
Recruiting
Phase 2 ORKA-002
Plaque Psoriasis · NCT07933783
July 2029
Enrolling
Phase 2 ORKA-001
Plaque Psoriasis · NCT07449702
May 2030
Recruiting

Cash position

Oruka Therapeutics Inc. reported $1.21B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $50M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-10-26

Companies working on similar indications

Discussion

No messages yet. If you follow ORKA, you can start the conversation.
Track ORKA in real time
See live implied volatility for ORKA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ORKA
Contact — questions or corrections about ORKA: dukeupt@gmail.com